NanoHybrids Launches Its First Product Line of Imaging Contrast Agents
NanoHybrids develops plasmonic gold nanoparticle contrast agents for photoacoustics, optical imaging, molecular diagnostics and other biological applications.
March 4, 2014 (Newswire.com) - NanoHybrids Corporation, a provider of nanotechnology-based contrast agents announced the launch of its new website and premium product line of gold nanoparticles specially designed to improve imaging results. The company's initial technology platform was developed in collaboration with researchers from the Biomedical Engineering Department at The University of Texas at Austin and M.D. Anderson Cancer Center.
"Frustrated by inconsistent imaging results due to highly variable shape, size and other properties of commercially available gold nanoparticle contrast agents, our team has developed highly monodisperse gold nanorods and nanospheres that will help scientists obtain consistent and better quality data. We also have a policy of 'no proprietary coatings' which means that unlike some companies in this space, we offer full transparency on surface chemistry, making it easier for our customers to modify and use these particles depending on their application," says Co-founder and Chief Technology Officer Dr. Kimberly Homan.
NanoHybrids' offerings include an exclusive line of silica-coated gold nanorods that are quickly gaining popularity as contrast agents in photoacoustic (optoacoustic) imaging. As opposed to current preclinical imaging contrast agents on the market, NanoHybrids' silica-coated nanorods resist melting and shape distortion even when subjected to extreme heat via focused laser beams. In addition to providing this enhanced thermodynamic stability, the silica-coating also facilitates better heat transfer to the surrounding fluid, thus dramatically increasing signal strength. Overall, these benefits make the company's silica-coated gold nanorods an excellent contrast agent for not only in vitro and in vivo photoacoustic imaging but also many other applications involving continuous or pulsed lasers.
The founders at NanoHybrids have decades of experience in biomedical imaging and have been pioneering the development of contrast agents alongside custom designed imaging systems. "Our products have been developed by imaging researchers, for researchers. As scientists ourselves, we understand the challenges involved when working with gold nanoparticles in imaging and strive to provide the highest possible level of quality and technical support," says Homan.
About NanoHybrids Inc.: NanoHybrids is an Austin-based company focused on commercializing nanotechnology solutions that can enhance the non-invasive detection and molecular profiling of cancer, atherosclerosis and other diseases. The company's current product line comprises of nano-sized agents that enhance contrast in pre-clinical biomedical imaging techniques by interacting specifically with diseased cells and allowing for selective real-time imaging of functional biology.
Product Applications: http://nanohybrids.net/pages/applications
Contact information: info at nanohybrids.net